The Role of Gwas Identified 5P15 Locus in Prostate Cancer Risk and Progression

Total Page:16

File Type:pdf, Size:1020Kb

The Role of Gwas Identified 5P15 Locus in Prostate Cancer Risk and Progression THE ROLE OF GWAS IDENTIFIED 5P15 LOCUS IN PROSTATE CANCER RISK AND PROGRESSION Panchadsaram Janaththani BSc in Molecular Biology and Biotechnology Submitted in fulfilment of the requirements for the degree of Doctor of Philosophy Institute of Health and Biomedical Innovation School of Biomedical Sciences Faculty of Health Queensland University of Technology 2019 Keywords 5p15 locus, Iroquois Homeobox 4, IRX4, IRX4lncRNA, Genome-Wide Association Studies, Multiple Nucleotide Length Polymorphism, Single nucleotide polymorphism, Prostate cancer, Long non-coding RNA, Androgens, ERG. The role of gwas identified 5p15 locus in prostate cancer risk and progression i Abstract Prostate cancer is the second most common cause of cancer death in Australian men. Androgens and the androgen receptor (AR) play a critical role in prostate cancer pathogenesis. Genome-wide association studies (GWAS) have led to the identification of 150 loci associated with prostate cancer risk. Through these GWAS, the rs12653946 SNP at the 5p15 locus was found to be significantly associated with prostate cancer risk in multi ethnic populations. The rs12653946 SNP genotype had also been correlated with the expression levels of its downstream gene Iroquois Homeobox 4 (IRX4) and its antisense long non-coding RNA, IRX4lncRNA. Interestingly, expression of IRX4 and IRX4lncRNA was found to be increased following castration in the LNCaP tumour progression mice model. Therefore, we hypothesised that the prostate cancer risk associated 5p15 locus confers its risk via IRX4 and IRX4lncRNA. The aim of this study was to determine the functional role of IRX4 and IRX4lncRNA in prostate cancer progression and to characterise their androgen-mediated expression regulation in prostate cancer cells. The studies in this thesis have shown that IRX4 and IRX4lncRNA were overexpressed in prostate tumour samples compared to adjacent non-malignant tissues. The expression of IRX4 was correlated with the ERG-fusion status, a prostate cancer specific fusion, while IRX4lncRNA expression was correlated with aggressive disease. The transient knockdown of IRX4 in LNCaP prostate cancer cells reduced cell proliferation and migration. Gene microarray analysis of IRX4 knockdown LNCaP samples revealed that the AR pathway was inhibited, suggesting IRX4 may mediate effective androgen signalling. This was further strengthened by an IRX4 immunoprecipitation assay, in which IRX4 was found to be interacting with the AR co-factors including, FOXA1. Similarly, knockdown of IRX4lncRNA reduced proliferation and migration of LNCaP cells, while overexpression of IRX4lncRNA increased PC3 cell proliferation, suggesting a tumour promoting role for this lncRNA. Both IRX4 and IRX4lncRNA expression were up-regulated with androgen (DHT) treatment in VCaP and DuCaP cells, but down-regulated in LNCaP cells. Interestingly, in-silico analysis identified binding of AR and ERG, upstream of IRX4 in VCaP and DuCaP cells, but not in LNCaP cells. Sequencing of this region identified a Multiple- ii The role of gwas identified 5p15 locus in prostate cancer risk and progression Nucleotide Length Polymorphism (MNLP-rs386684493), where a stretch of 47bp sequence was replaced by a novel 21bp sequence. VCaP and DuCaP cells have an intact AR binding site whereas LNCaP cells have a disrupted AR binding site, suggesting this MNLP may be the functional variant guiding AR binding at this locus. The androgen responsiveness of MNLP was further confirmed by a reporter vector assay. Large-scale genetic association studies of this MNLP in ~80,000 men through the PRACTICAL Consortium identified the MNLP as the most significant prostate cancer risk associated variant at this locus. Furthermore, the 21bp/21bp genotype was correlated with lower expression levels of IRX4 and IRX4lncRNA and poor survival outcome in those patients who underwent androgen deprivation therapy. IRX4 expression was also correlated with ERG-fusion status in prostate cancer datasets, which was also confirmed in our prostate cancer tissue samples. ERG knockdown in VCaP and DuCaP cells increased the androgen-mediated up-regulation of IRX4 expression, while ERG overexpression in LNCaP cells reduced IRX4 expression independent of androgen treatment. In summary, our study identified IRX4 as a potential mediator of effective androgen signalling and targeting IRX4 in patients stratified for ERG-fusion status and MNLP genotype may be a novel therapeutic strategy. In addition, this study discovered the functional role of IRX4lncRNA and identifying molecular mechanisms of this lncRNA in prostate cancer pathology may provide insights for the development of biologically meaningful targets for new therapeutics. The role of gwas identified 5p15 locus in prostate cancer risk and progression iii Table of Contents Keywords .................................................................................................................................. i Abstract .................................................................................................................................... ii List of Figures ........................................................................................................................ vii List of Tables ............................................................................................................................ x List of Abbreviations ............................................................................................................... xi Statement of Original Authorship ......................................................................................... xiv Awards and Publications ........................................................................................................ xv Acknowledgements .............................................................................................................. xvii Chapter 1: Literature Review ................................................................................... 1 1.1. Prostate Cancer .................................................................................................................. 1 1.1.1. Prostate cancer staging and grading ..................................................................... 1 1.1.2. Diagnosis ............................................................................................................. 2 1.1.3. Treatment ............................................................................................................. 2 1.2. The role of the androgen receptor in the progression of prostate cancer........................... 3 1.3. The role of TMPRSS2-ERG fusion in prostate cancer ..................................................... 4 1.4. Prostate cancer risk factors ................................................................................................ 6 1.5. Genome-Wide Association Studies (GWAS) ................................................................... 6 1.6. The rs12653946 SNP at the 5p15 locus is associated with prostate cancer risk ............... 7 1.7. Iroquois Homeobox 4 (IRX4) .......................................................................................... 11 1.8. Antisense long non-coding RNA, IRX4lncRNA, at 5p15 locus ....................................... 16 1.9. Long non-coding RNAs (lncRNAs) ................................................................................ 17 1.10. Summary and knowledge gap ....................................................................................... 33 1.11. Hypothesis and Aims..................................................................................................... 34 Chapter 2: Materials and Methods ......................................................................... 35 2.1. Cell culture ...................................................................................................................... 35 2.2. Genomic DNA samples for genetic association studies .................................................. 35 2.3. RNA isolation from FFPE prostate tumour tissues and matched controls ...................... 36 2.4. RNA isolation from cell lines .......................................................................................... 36 2.5. cDNA synthesis ............................................................................................................... 36 2.6. Reverse transcription polymerase chain reaction (RT-PCR) .......................................... 37 2.7. Quantitative RT-PCR (qRT-PCR) ................................................................................... 37 2.8. Western blot .................................................................................................................... 38 2.9. siRNA mediated knockdown ........................................................................................... 38 2.10. Proliferation assay ......................................................................................................... 39 2.11. Migration assay ............................................................................................................. 39 2.12. Statistical analysis ......................................................................................................... 40 iv The role of gwas identified 5p15 locus in prostate cancer risk and progression Chapter 3: The role of Iroquois-Homeobox 4 (IRX4) at the GWAS identified 5p15 locus in prostate cancer .................................................................................
Recommended publications
  • Genome-Wide Association Study of Behavioral Disinhibition in a Selected Adolescent Sample Jaime Derringer *, Robin P. Corley
    Genome-wide association study of behavioral disinhibition in a selected adolescent sample Jaime Derringer1*, Robin P. Corley2, Brett C. Haberstick2, Susan E. Young2, Brittany Demmitt2, Daniel P. Howrigan3, Robert M. Kirkpatrick4, William G. Iacono5, Matt McGue5, Matthew Keller2, Sandra Brown6, Susan Tapert6, Christian J. Hopfer7, Michael C. Stallings2, Thomas J. Crowley7, Soo Hyun Rhee2, Ken Krauter2, John K. Hewitt2, Matthew B. McQueen2 1 University of Illinois Urbana-Champaign, 2 University of Colorado Boulder, 3 Massachusetts General Hospital/Harvard Medical School, 4 Virginia Commonwealth University, 5 University of Minnesota, 6 University of California San Diego, 7 University of Colorado Denver * Corresponding Author: Jaime Derringer, [email protected], Department of Psychology, University of Illinois Urbana-Champaign, Champaign IL USA 61820 Behavioral disinhibition GWAS 2 Abstract Behavioral disinhibition (BD) is a quantitative measure designed to capture the heritable variation encompassing risky and impulsive behaviors. As a result, BD represents an ideal target for discovering genetic loci that predispose individuals to a wide range of antisocial behaviors and substance misuse that together represent a large cost to society as a whole. Published genome-wide association studies (GWAS) have examined specific phenotypes that fall under the umbrella of BD (e.g. alcohol dependence, conduct disorder); however no GWAS has specifically examined the overall BD construct. We conducted a GWAS of BD using a sample of 1,901 adolescents over-selected for characteristics that define high BD, such as substance and antisocial behavior problems, finding no individual locus that surpassed genome-wide significance. Although no single SNP was significantly associated with BD, restricted maximum likelihood analysis estimated that 49.3% of the variance in BD within the Caucasian sub-sample was accounted for by the genotyped SNPs (p=0.06).
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Molecular Characterization of Acute Myeloid Leukemia by Next Generation Sequencing: Identification of Novel Biomarkers and Targets of Personalized Therapies
    Alma Mater Studiorum – Università di Bologna Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Dottorato di Ricerca in Oncologia, Ematologia e Patologia XXX Ciclo Settore Scientifico Disciplinare: MED/15 Settore Concorsuale:06/D3 Molecular characterization of acute myeloid leukemia by Next Generation Sequencing: identification of novel biomarkers and targets of personalized therapies Presentata da: Antonella Padella Coordinatore Prof. Pier-Luigi Lollini Supervisore: Prof. Giovanni Martinelli Esame finale anno 2018 Abstract Acute myeloid leukemia (AML) is a hematopoietic neoplasm that affects myeloid progenitor cells and it is one of the malignancies best studied by next generation sequencing (NGS), showing a highly heterogeneous genetic background. The aim of the study was to characterize the molecular landscape of 2 subgroups of AML patients carrying either chromosomal number alterations (i.e. aneuploidy) or rare fusion genes. We performed whole exome sequencing and we integrated the mutational data with transcriptomic and copy number analysis. We identified the cell cycle, the protein degradation, response to reactive oxygen species, energy metabolism and biosynthetic process as the pathways mostly targeted by alterations in aneuploid AML. Moreover, we identified a 3-gene expression signature including RAD50, PLK1 and CDC20 that characterize this subgroup. Taking advantage of RNA sequencing we aimed at the discovery of novel and rare gene fusions. We detected 9 rare chimeric transcripts, of which partner genes were transcription factors (ZEB2, BCL11B and MAFK) or tumor suppressors (SAV1 and PUF60) rarely translocated across cancer types. Moreover, we detected cryptic events hiding the loss of NF1 and WT1, two recurrently altered genes in AML. Finally, we explored the oncogenic potential of the ZEB2-BCL11B fusion, which revealed no transforming ability in vitro.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Appendix 2. Significantly Differentially Regulated Genes in Term Compared with Second Trimester Amniotic Fluid Supernatant
    Appendix 2. Significantly Differentially Regulated Genes in Term Compared With Second Trimester Amniotic Fluid Supernatant Fold Change in term vs second trimester Amniotic Affymetrix Duplicate Fluid Probe ID probes Symbol Entrez Gene Name 1019.9 217059_at D MUC7 mucin 7, secreted 424.5 211735_x_at D SFTPC surfactant protein C 416.2 206835_at STATH statherin 363.4 214387_x_at D SFTPC surfactant protein C 295.5 205982_x_at D SFTPC surfactant protein C 288.7 1553454_at RPTN repetin solute carrier family 34 (sodium 251.3 204124_at SLC34A2 phosphate), member 2 238.9 206786_at HTN3 histatin 3 161.5 220191_at GKN1 gastrokine 1 152.7 223678_s_at D SFTPA2 surfactant protein A2 130.9 207430_s_at D MSMB microseminoprotein, beta- 99.0 214199_at SFTPD surfactant protein D major histocompatibility complex, class II, 96.5 210982_s_at D HLA-DRA DR alpha 96.5 221133_s_at D CLDN18 claudin 18 94.4 238222_at GKN2 gastrokine 2 93.7 1557961_s_at D LOC100127983 uncharacterized LOC100127983 93.1 229584_at LRRK2 leucine-rich repeat kinase 2 HOXD cluster antisense RNA 1 (non- 88.6 242042_s_at D HOXD-AS1 protein coding) 86.0 205569_at LAMP3 lysosomal-associated membrane protein 3 85.4 232698_at BPIFB2 BPI fold containing family B, member 2 84.4 205979_at SCGB2A1 secretoglobin, family 2A, member 1 84.3 230469_at RTKN2 rhotekin 2 82.2 204130_at HSD11B2 hydroxysteroid (11-beta) dehydrogenase 2 81.9 222242_s_at KLK5 kallikrein-related peptidase 5 77.0 237281_at AKAP14 A kinase (PRKA) anchor protein 14 76.7 1553602_at MUCL1 mucin-like 1 76.3 216359_at D MUC7 mucin 7,
    [Show full text]
  • Misexpression of Cancer/Testis (Ct) Genes in Tumor Cells and the Potential Role of Dream Complex and the Retinoblastoma Protein Rb in Soma-To-Germline Transformation
    Michigan Technological University Digital Commons @ Michigan Tech Dissertations, Master's Theses and Master's Reports 2019 MISEXPRESSION OF CANCER/TESTIS (CT) GENES IN TUMOR CELLS AND THE POTENTIAL ROLE OF DREAM COMPLEX AND THE RETINOBLASTOMA PROTEIN RB IN SOMA-TO-GERMLINE TRANSFORMATION SABHA M. ALHEWAT Michigan Technological University, [email protected] Copyright 2019 SABHA M. ALHEWAT Recommended Citation ALHEWAT, SABHA M., "MISEXPRESSION OF CANCER/TESTIS (CT) GENES IN TUMOR CELLS AND THE POTENTIAL ROLE OF DREAM COMPLEX AND THE RETINOBLASTOMA PROTEIN RB IN SOMA-TO- GERMLINE TRANSFORMATION", Open Access Master's Thesis, Michigan Technological University, 2019. https://doi.org/10.37099/mtu.dc.etdr/933 Follow this and additional works at: https://digitalcommons.mtu.edu/etdr Part of the Cancer Biology Commons, and the Cell Biology Commons MISEXPRESSION OF CANCER/TESTIS (CT) GENES IN TUMOR CELLS AND THE POTENTIAL ROLE OF DREAM COMPLEX AND THE RETINOBLASTOMA PROTEIN RB IN SOMA-TO-GERMLINE TRANSFORMATION By Sabha Salem Alhewati A THESIS Submitted in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE In Biological Sciences MICHIGAN TECHNOLOGICAL UNIVERSITY 2019 © 2019 Sabha Alhewati This thesis has been approved in partial fulfillment of the requirements for the Degree of MASTER OF SCIENCE in Biological Sciences. Department of Biological Sciences Thesis Advisor: Paul Goetsch. Committee Member: Ebenezer Tumban. Committee Member: Zhiying Shan. Department Chair: Chandrashekhar Joshi. Table of Contents List of figures .......................................................................................................................v
    [Show full text]
  • Supplementary Material Computational Prediction of SARS
    Supplementary_Material Computational prediction of SARS-CoV-2 encoded miRNAs and their putative host targets Sheet_1 List of potential stem-loop structures in SARS-CoV-2 genome as predicted by VMir. Rank Name Start Apex Size Score Window Count (Absolute) Direct Orientation 1 MD13 2801 2864 125 243.8 61 2 MD62 11234 11286 101 211.4 49 4 MD136 27666 27721 104 205.6 119 5 MD108 21131 21184 110 204.7 210 9 MD132 26743 26801 119 188.9 252 19 MD56 9797 9858 128 179.1 59 26 MD139 28196 28233 72 170.4 133 28 MD16 2934 2974 76 169.9 71 43 MD103 20002 20042 80 159.3 403 46 MD6 1489 1531 86 156.7 171 51 MD17 2981 3047 131 152.8 38 87 MD4 651 692 75 140.3 46 95 MD7 1810 1872 121 137.4 58 116 MD140 28217 28252 72 133.8 62 122 MD55 9712 9758 96 132.5 49 135 MD70 13171 13219 93 130.2 131 164 MD95 18782 18820 79 124.7 184 173 MD121 24086 24135 99 123.1 45 176 MD96 19046 19086 75 123.1 179 196 MD19 3197 3236 76 120.4 49 200 MD86 17048 17083 73 119.8 428 223 MD75 14534 14600 137 117 51 228 MD50 8824 8870 94 115.8 79 234 MD129 25598 25642 89 115.6 354 Reverse Orientation 6 MR61 19088 19132 88 197.8 271 10 MR72 23563 23636 148 188.8 286 11 MR11 3775 3844 136 185.1 116 12 MR94 29532 29582 94 184.6 271 15 MR43 14973 15028 109 183.9 226 27 MR14 4160 4206 89 170 241 34 MR35 11734 11792 111 164.2 37 52 MR5 1603 1652 89 152.7 118 53 MR57 18089 18132 101 152.7 139 94 MR8 2804 2864 122 137.4 38 107 MR58 18474 18508 72 134.9 237 117 MR16 4506 4540 72 133.8 311 120 MR34 10010 10048 82 132.7 245 133 MR7 2534 2578 90 130.4 75 146 MR79 24766 24808 75 127.9 59 150 MR65 21528 21576 99 127.4 83 180 MR60 19016 19049 70 122.5 72 187 MR51 16450 16482 75 121 363 190 MR80 25687 25734 96 120.6 75 198 MR64 21507 21544 70 120.3 35 206 MR41 14500 14542 84 119.2 94 218 MR84 26840 26894 108 117.6 94 Sheet_2 List of stable stem-loop structures based on MFE.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,476,099 B2 Spinella Et Al
    US009476.099B2 (12) United States Patent (10) Patent No.: US 9,476,099 B2 Spinella et al. (45) Date of Patent: Oct. 25, 2016 (54) METHOD FOR DETERMINING FOREIGN PATENT DOCUMENTS SENSTIVITY TO DECTABINE WO WO 2012/031008 A2 3, 2012 TREATMENT WO WO 2012, 11885.6 A1 9, 2012 (71) Applicant: TRUSTEES OF DARTMOUTH COLLEGE, Hanover, NH (US) OTHER PUBLICATIONS (72) Inventors: Michael Spinella, Hanover, NH (US); Tsai et al Cancer Cell. Mar. 20, 2012. 21(3):43.0-446 and Supple Maroun J. Beyrouthy, Lebanon, NH mental pages 1-18. (US) Agilent Technologies. DNA Oligo Microarray Gene Lists and Annotations, available via url: <chem.agilent.com/cag?bSp? gene (73) Assignee: Trustees of Dartmouth College, lists.asp printed on Mar. 1, 2016.* Hanover, NH (US) Abele et al. “The EORTC Early Clinical Trials Cooperative Group Experience with 5-Aza-2'-deoxycytidine (NSC 127716) in Patients (*) Notice: Subject to any disclaimer, the term of this with Colo-rectal, Head and Neck, Renal Carcinomas and Malignant patent is extended or adjusted under 35 Melanomas' European Journal of Cancer and Clinical Oncology U.S.C. 154(b) by 0 days. 1987 23(12): 1921-1924. Adewumi et al. “Characterization of Human Embryonic Stem Cell (21) Appl. No.: 14/416,142 Lines by the International StemCell Initiative” Nature Biotechnol ogy 2007 vol. 25(7):803-816. (22) PCT Filed: Jul. 31, 2013 Al-Hajj et al. "Prospective Identification of Tumorigenic Breast Cancer Cells' Proceedings of the National Academy of Sciences (86). PCT No.: PCT/US2013/052899 2003 100(7):3983-3988 with correction.
    [Show full text]
  • Strand Breaks for P53 Exon 6 and 8 Among Different Time Course of Folate Depletion Or Repletion in the Rectosigmoid Mucosa
    SUPPLEMENTAL FIGURE COLON p53 EXONIC STRAND BREAKS DURING FOLATE DEPLETION-REPLETION INTERVENTION Supplemental Figure Legend Strand breaks for p53 exon 6 and 8 among different time course of folate depletion or repletion in the rectosigmoid mucosa. The input of DNA was controlled by GAPDH. The data is shown as ΔCt after normalized to GAPDH. The higher ΔCt the more strand breaks. The P value is shown in the figure. SUPPLEMENT S1 Genes that were significantly UPREGULATED after folate intervention (by unadjusted paired t-test), list is sorted by P value Gene Symbol Nucleotide P VALUE Description OLFM4 NM_006418 0.0000 Homo sapiens differentially expressed in hematopoietic lineages (GW112) mRNA. FMR1NB NM_152578 0.0000 Homo sapiens hypothetical protein FLJ25736 (FLJ25736) mRNA. IFI6 NM_002038 0.0001 Homo sapiens interferon alpha-inducible protein (clone IFI-6-16) (G1P3) transcript variant 1 mRNA. Homo sapiens UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 15 GALNTL5 NM_145292 0.0001 (GALNT15) mRNA. STIM2 NM_020860 0.0001 Homo sapiens stromal interaction molecule 2 (STIM2) mRNA. ZNF645 NM_152577 0.0002 Homo sapiens hypothetical protein FLJ25735 (FLJ25735) mRNA. ATP12A NM_001676 0.0002 Homo sapiens ATPase H+/K+ transporting nongastric alpha polypeptide (ATP12A) mRNA. U1SNRNPBP NM_007020 0.0003 Homo sapiens U1-snRNP binding protein homolog (U1SNRNPBP) transcript variant 1 mRNA. RNF125 NM_017831 0.0004 Homo sapiens ring finger protein 125 (RNF125) mRNA. FMNL1 NM_005892 0.0004 Homo sapiens formin-like (FMNL) mRNA. ISG15 NM_005101 0.0005 Homo sapiens interferon alpha-inducible protein (clone IFI-15K) (G1P2) mRNA. SLC6A14 NM_007231 0.0005 Homo sapiens solute carrier family 6 (neurotransmitter transporter) member 14 (SLC6A14) mRNA.
    [Show full text]
  • A Bacterial Protein Targets the BAHD1 Chromatin Complex to Stimulate Type III Interferon Response
    A bacterial protein targets the BAHD1 chromatin complex to stimulate type III interferon response Alice Lebreton, Goran Lakisic, Viviana Job, Lauriane Fritsch, To Nam Tham, Ana Camejo, Pierre-Jean Matteï, Béatrice Regnault, Marie-Anne Nahori, Didier Cabanes, et al. To cite this version: Alice Lebreton, Goran Lakisic, Viviana Job, Lauriane Fritsch, To Nam Tham, et al.. A bacterial protein targets the BAHD1 chromatin complex to stimulate type III interferon response. Science, American Association for the Advancement of Science, 2011, 331 (6022), pp.1319-21. 10.1126/sci- ence.1200120. cea-00819299 HAL Id: cea-00819299 https://hal-cea.archives-ouvertes.fr/cea-00819299 Submitted on 26 Jul 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Lebreton et al. Science 2011 doi:10.1126/science.1200120 A Bacterial Protein Targets the BAHD1 Chromatin Complex to Stimulate Type III Interferon Response Alice Lebreton1,2,3, Goran Lakisic4, Viviana Job5, Lauriane Fritsch6, To Nam Tham1,2,3, Ana Camejo7, Pierre-Jean Matteï5, Béatrice Regnault8, Marie-Anne Nahori1,2,3, Didier Cabanes7, Alexis Gautreau4, Slimane Ait-Si-Ali6, Andréa Dessen5, Pascale Cossart1,2,3* and Hélène Bierne1,2,3* 1.
    [Show full text]
  • Genomic Architecture of Histone 3 Lysine 27 Trimethylation During Late Ovine Skeletal Muscle Development
    doi: 10.1111/age.12145 Genomic architecture of histone 3 lysine 27 trimethylation during late ovine skeletal muscle development † ‡ K. Byrne*1, S. McWilliam*1, T. Vuocolo*, C. Gondro , N. E. Cockett and R. L. Tellam* † *CSIRO Animal, Food and Health Sciences, Queensland Bioscience Precinct, 306 Carmody Rd, St Lucia, QLD, 4067, Australia. School of ‡ Environmental and Rural Science, University of New England, Armidale, NSW, Australia. Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA. Summary The ruminant developmental transition from late foetus to lamb is associated with marked changes in skeletal muscle structure and function that reflect programming for new physiological demands following birth. To determine whether epigenetic changes are involved in this transition, we investigated the genomic architecture of the chromatin modification, histone 3 lysine 27 trimethylation (H3K27me3), which typically regulates early life developmental processes; however, its role in later life processes is unclear. Chromatin immunoprecipitation coupled with next-generation sequencing was used to map H3K27me3 nucleosomes in ovine longissimus lumborum skeletal muscle at 100 days of gestation and 12 weeks post-partum. In both states, H3K27me3 modification was associated with genes, transcription start sites and CpG islands and with transcriptional silencing. The H3K27me3 peaks consisted of two major categories, promoter specific and regional, with the latter the dominant feature. Genes encoding homeobox transcription factors regulating early life development and genes involved in neural functions, particularly gated ion channels, were strongly modified by H3K27me3. Gene promoters differentially modified by H3K27me3 in the foetus and lamb were enriched for gated ion channels, which may reflect changes in neuromuscular function.
    [Show full text]
  • Directed Differentiation of Human Embryonic Stem Cells Into Haematopoietic and Definitive Endodermal Lineages
    DIRECTED DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS INTO HAEMATOPOIETIC AND DEFINITIVE ENDODERMAL LINEAGES ABRAHAM SUMAN MARY (M.Sc MICROBIOLOGY, UNIV. OF MUMBAI, INDIA) A THESIS SUBMITTED FOR THE DEGREE OF MASTER OF SCIENCE DEPARTMENT OF BIOCHEMISTRY NATIONAL UNIVERSITY OF SINGAPORE 2009 ACKNOWLEDGEMENTS In all things I give YOU glory! You have always led me through amazing paths and given me gifts that I don’t deserve. I thank you Lord for all the blessings you constantly shower on me. Everything is possible with God! I thank Dr. Alan Colman for being my guide and helping me to initiate the work contained in this dissertation. His support and encouragement have been invaluable. Thank you, Alan for your support through the years. Dr. Norris Ray Dunn took me under his wing and guided me through this endeavour. He has been a true mentor, always willing to teach, and I have learned a lot from him. Ray, thank you for showing me the way and helping me reach this juncture. A significant part of the research was conducted at ES Cell International Pte Ltd to whom I would like to express my sincere gratitude. Triona, Jacqui, Robert, Michael, Bruce, Chirag, Suzan and so many others have played important roles and encouraged me at all times. Critical portions of this work were done at the Institute of Medical Biology, A*Star. I would like to register my appreciation for the support and help provided by many people in IMB especially, members of the Ray Dunn lab, Mike Jones lab and Alan Colman lab. Kee Yew, thank you for giving me your precious time and helping me with some of the most important data in this dissertation.
    [Show full text]